Document is current
Any future updates will be listed below
-
Authors
Mantovani, Alberto https://orcid.org/0000-0001-5578-236X
Marchesi, Federica
Di Mitri, Diletta
Garlanda, Cecilia
- License Information
-
More Information
Article History
Received: 3 July 2024
Accepted: 6 September 2024
First Online: 14 October 2024
Competing interests
: AM has been a recipient of commercial research grants from Sigma Tau, Roche, Novartis, Compugen and Efranat, and has been a consultant/advisory board member/lecturer for Novartis, Roche, Ventana, Pierre Fabre, Verily, Abbvie, BMS, J&J, Compugen, Imcheck, Macrophage Therapeutics, AstraZeneca, Biovelocita, BG Fund, Third Rock, Verseau Therapeutics and Olatec Therapeutics. CG is recipient of research grants from Imcheck and Macrophage Therapeutics. AM and CG receive royalties for reagents related to innate immunity.
